Merck, Inc.
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04665037
- Locations
- 🇺🇦
NATIONAL CHILDREN'S SPECIALIZED HOSPITAL "OKHMATDYT" OF THE -Intensive Care Unit ( Site 1912), Kiev, Kyiv, Ukraine
🇺🇸Rady Children's Hospital-San Diego ( Site 2101), San Diego, California, United States
🇺🇸Nicklaus Children's Hospital ( Site 2109), Miami, Florida, United States
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 102
- Registration Number
- NCT04665050
- Locations
- 🇯🇵
Souseikai Nishikumamoto Hospital ( Site 0202), Kumamoto, Japan
🇯🇵Souseikai PS Clinic ( Site 0201), Fukuoka, Japan
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 890
- Registration Number
- NCT04662710
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0003), Los Angeles, California, United States
🇦🇺Nepean Hospital ( Site 2305), Kingswood, New South Wales, Australia
🇺🇸Mount Sinai Hospital ( Site 0051), New York, New York, United States
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
- Conditions
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 494
- Registration Number
- NCT04652700
- Locations
- 🇺🇸
Howard Brown Health Center ( Site 0004), Chicago, Illinois, United States
🇿🇦Desmond Tutu HIV Foundation ( Site 0202), Cape Town, Western Cape, South Africa
🇺🇸Bridge HIV - San Francisco Department of Public Health ( Site 0003), San Francisco, California, United States
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 730
- Registration Number
- NCT04644029
- Locations
- 🇺🇬
MU-JHU Care Limited-Clinic ( Site 0041), Kampala, Uganda
🇿🇦Madibeng Centre for Research ( Site 0019), Brits, North-West, South Africa
🇿🇦Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023), Johannesburg, Gauteng, South Africa
Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)
- Conditions
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1059
- Registration Number
- NCT04635423
- Locations
- 🇯🇵
Kanno Clinic ( Site 6402), Sakai, Osaka, Japan
🇯🇵Seiyukai Medical Corporation Itoh Skin Clinic ( Site 6416), Tokyo, Japan
🇯🇵P-One Clinic, Keikokai Medical Corp. ( Site 6419), Hachioji, Tokyo, Japan
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 990
- Registration Number
- NCT04634877
- Locations
- 🇨🇦
Kingston Health Sciences Centre ( Site 3003), Kingston, Ontario, Canada
🇺🇸University of South Alabama, Mitchell Cancer Institute ( Site 3058), Mobile, Alabama, United States
🇺🇸WK Physicians Network/Gynecologic Oncology Associates ( Site 3047), Shreveport, Louisiana, United States
Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT04633226
- Locations
- 🇰🇷
Jeonbuk National University Hospital ( Site 0008), Jeonju-si, Jeonrabugdo, Korea, Republic of
🇰🇷Hallym University Dongtan Sacred Heart Hospital ( Site 0013), Hwaseong-si, Kyonggi-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center CHA University ( Site 0020), Seongnam si, Kyonggi-do, Korea, Republic of
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 370
- Registration Number
- NCT04626518
- Locations
- 🇺🇸
UTSW Medical Center ( Site 3003), Dallas, Texas, United States
🇺🇸University of Chicago ( Site 3013), Chicago, Illinois, United States
🇺🇸Yale-New Haven Hospital-Yale Cancer Center ( Site 3011), New Haven, Connecticut, United States
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT04626479
- Locations
- 🇳🇱
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402), Amsterdam, Noord-Holland, Netherlands
🇨🇱CIDO SpA-Oncology ( Site 2106), Temuco, Araucania, Chile
🇬🇧The Christie NHS Foundation Trust ( Site 1400), Manchester, United Kingdom